ArticleJournal of geriatric oncology2015
Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.
Article in Journal of geriatric oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04602273 (Treatment of High Risk Myelodysplastic Syndromes), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.Blood advances · 2023Trial
- [Prognostic value of the FS-15 frailty score in patients with myelodysplastic syndromes].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes.JCO oncology practice · 2023Article
- Peripheral blood CD3British journal of haematology · 2022Article
- Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes.Journal of patient-reported outcomes · 2020Article
- An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring.Leukemia · 2020Article
- Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis.European journal of haematology · 2020Review
- Integrating patient-centered factors in the risk assessment of MDS.Hematology. American Society of Hematology. Education Program · 2019Review
- The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.Blood advances · 2018Article
- Article
- Frailty measure is more predictive of outcomes after curative therapy for endometrial cancer than traditional risk factors in women 60 and older.Gynecologic oncology · 2017Article
- Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly.Clinics in geriatric medicine · 2016Review
- From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008-2023).American journal of men's healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
objectivesThe International Prognostic Scoring System (IPSS) is commonly used to predict survival and assign treatment for the myelodysplastic syndromes (MDS). We explored whether self-reported and readily available non-hematologic predictors of survival add independent prognostic information to the IPSS. MATERIALS AND
methodsRetrospective cohort study of consecutive MDS patients ≥age 65 who presented to Dana-Farber Cancer Institute between 2006 and 2011 and completed a baseline quality of life questionnaire. Questions corresponding to functional status and symptoms and extracted clinical-pathologic data from medical records. Kaplan-Meier and Cox proportional hazards models were used to estimate survival.
resultsOne hundred fourteen patients consented and were available for analysis. Median age was 73 years, and the majority of patients were White, were male, and had a Charlson comorbidity score of <2. Few patients (24%) had an IPSS score consistent with lower-risk disease and the majority received chemotherapy. In addition to IPSS score and history of prior chemotherapy or radiation, significant univariate predictors of survival included low serum albumin, Charlson score, performance status, ability to take a long walk, and interference of physical symptoms in family life. The multivariate model that best predicted mortality included low serum albumin (HR=2.3; 95% CI: 1.06-5.14), therapy-related MDS (HR=2.1; 95% CI: 1.16-4.24), IPSS score (HR=1.7; 95% CI: 1.14-2.49), and ease taking a long walk (HR=0.44; 95% CI: 0.23-0.90).
conclusionsIn this study of older adults with MDS, we found that low serum albumin and physical function added important prognostic information to the IPSS score. Self-reported physical function was more predictive than physician-assigned performance status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.